Hidoc Dr | Medical Learning App for Doctors

Today's Updates

Metabolic Agent Vutiglabridin Improves Motor Scores in Early-Stage Study of Parkinson Disease Marco Meglio

Published Date: 09 Oct 2026

Phase 2a trial results showed 800 mg vutiglabridin significantly improved motor symptom scores compared with placebo in early-stage Parkinson's disease.

New Study Reveals Plasma Biomarkers Highlight Distinct Biological Responses to Lecanemab in Alzheimer Disease Louie Pasculli, Carlos Cruchaga, PhD

Published Date: 09 Oct 2026

Carlos Cruchaga, PhD, director of the NeuroGenomics and Informatics Center at Washington University, discusses emerging blood-based biomarkers for monitoring biological and cognitive responses to lecanemab treatment in Alzheimer disease.

Christen Kutz, PhD, PA-C, on What Real-World Data Reveal About Treatment Transitions to Nipocalimab in Generalized Myasthenia Gravis Marco Meglio, Christen Kutz, PhD, PA-C

Published Date: 09 Oct 2026

Christen Kutz, PhD, PA-C, discusses a retrospective survey of neurology providers examining why patients with generalized myasthenia gravis are transitioning to nipocalimab and what real-world outcomes data suggest about its role in the treatment landscape.

Brain Chat: The Overlap Years: Perimenopause, Menopause, and MS Mitzi Joi Williams, MD

Published Date: 09 Oct 2026

Mitzi Joi Williams, MD, is joined by Jakai McEwen, DO, and Charnetta Colton-Poole, MD, to discuss the challenges of communication between patients and their health care teams, including navigating medical language, promoting shared decision-making, and advocating for clear, patient-centered care.

Advanced Therapies in Parkinson Disease: Matching the Right Treatment to the Right Patient Hubert Fernandez, MD, Louie Pasculli

Published Date: 09 Oct 2026

An MDS 2026 plenary speaker discusses the evolving role of infusion therapies, deep brain stimulation, and focused ultrasound in Parkinson disease, including when to consider device-aided therapies and how treatment selection can be individualized.

Mistaken for a UTI: Diagnosing IgA Nephropathy, With Gaia Coppock, MD Gaia Coppock, MD

Published Date: 09 Oct 2026

A survey of patients with IgA nephropathy shows how nonspecific symptoms and long referral waits delay diagnosis by up to two years.

Moving Corticosteroid Stewardship into Policy, With Killian Lozach, MBA Killian Lozach, MBA

Published Date: 09 Oct 2026

Lozach outlines how the Corticosteroid Stewardship Alliance plans to bring clinician data and adverse event costs to payers and lawmakers.

Remibrutinib Receives FDA Approval for Symptomatic Dermographism

Published Date: 09 Oct 2026

Remibrutinib Receives FDA Approval for Symptomatic Dermographism

Conference Preview: Fall Clinical Dermatology Conference 2026

Published Date: 09 Oct 2026

Conference Preview: Fall Clinical Dermatology Conference 2026

Tips on Optimizing HS Biologics, Combinations, and Surgery

Published Date: 09 Oct 2026

Tips on Optimizing HS Biologics, Combinations, and Surgery

Knowledge Hub

Oncology

Toxicity Surveillance for Bispecific Cancer Therapies

Comprehensive review of toxicity surveillance strategies for bispecific cancer therapies in clinical practice.

Oncology

Case-Based Learning: Cancer-Associated Thrombosis During Noncytotoxic Therapy

Review of cancer-associated thrombosis during noncytotoxic therapy, highlighting mechanisms, management, and clinical guidance for healthcare professionals.

Oncology

Pharmacokinetic Optimization of Combination Cancer Therapy

Comprehensive review of strategies for pharmacokinetic optimization in combination cancer therapy for improved clinical outcomes.

Oncology

Monitoring Delayed Toxicity of Antibody Therapies

Comprehensive review of delayed toxicity monitoring in antibody therapies for clinicians.

Oncology

KOL Videos

Hidoc Dr| Hidoc- US| Hidoc - Doctor Netwoking Platform| Educational resource for HCPs

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug Database Drug Interaction Diseases Database

KOL Videos Knowledge Hub Quizzes

Medical Updates Events About Us

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation

Your one-stop Solution for MEDICAL LEARNING & UPDATES

Metabolic Agent Vutiglabridin Improves Motor Scores in Early-Stage Study of Parkinson Disease Marco Meglio

New Study Reveals Plasma Biomarkers Highlight Distinct Biological Responses to Lecanemab in Alzheimer Disease Louie Pasculli, Carlos Cruchaga, PhD

Christen Kutz, PhD, PA-C, on What Real-World Data Reveal About Treatment Transitions to Nipocalimab in Generalized Myasthenia Gravis Marco Meglio, Christen Kutz, PhD, PA-C

Brain Chat: The Overlap Years: Perimenopause, Menopause, and MS Mitzi Joi Williams, MD

Advanced Therapies in Parkinson Disease: Matching the Right Treatment to the Right Patient Hubert Fernandez, MD, Louie Pasculli

Mistaken for a UTI: Diagnosing IgA Nephropathy, With Gaia Coppock, MD Gaia Coppock, MD

Moving Corticosteroid Stewardship into Policy, With Killian Lozach, MBA Killian Lozach, MBA

Remibrutinib Receives FDA Approval for Symptomatic Dermographism

Conference Preview: Fall Clinical Dermatology Conference 2026

Tips on Optimizing HS Biologics, Combinations, and Surgery

Knowledge Hub

Toxicity Surveillance for Bispecific Cancer Therapies

Case-Based Learning: Cancer-Associated Thrombosis During Noncytotoxic Therapy

Pharmacokinetic Optimization of Combination Cancer Therapy

Monitoring Delayed Toxicity of Antibody Therapies

Personalized Oncolytic Virus Combinations: Current Evidence and Clinical Implications

Population Surveillance of Environmental Cancer Risk Clusters

Community Strategies for Improving Cancer Prevention Literacy

KOL Videos

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part IV

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Q & A Session

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part III

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II

An In-Depth Look At The Signs And Symptoms Of Lymphoma- Further Discussion

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII

Current Scenario of Cancer- Q&A Session to Close the Gap Part II

Quick Links

Page Views

Your one-stop Solution for MEDICAL LEARNING & UPDATES

Metabolic Agent Vutiglabridin Improves Motor Scores in Early-Stage Study of Parkinson Disease Marco Meglio

New Study Reveals Plasma Biomarkers Highlight Distinct Biological Responses to Lecanemab in Alzheimer Disease Louie Pasculli, Carlos Cruchaga, PhD

Christen Kutz, PhD, PA-C, on What Real-World Data Reveal About Treatment Transitions to Nipocalimab in Generalized Myasthenia Gravis Marco Meglio, Christen Kutz, PhD, PA-C

Brain Chat: The Overlap Years: Perimenopause, Menopause, and MS Mitzi Joi Williams, MD

Advanced Therapies in Parkinson Disease: Matching the Right Treatment to the Right Patient Hubert Fernandez, MD, Louie Pasculli

Mistaken for a UTI: Diagnosing IgA Nephropathy, With Gaia Coppock, MD Gaia Coppock, MD

Moving Corticosteroid Stewardship into Policy, With Killian Lozach, MBA Killian Lozach, MBA

Remibrutinib Receives FDA Approval for Symptomatic Dermographism

Conference Preview: Fall Clinical Dermatology Conference 2026

Tips on Optimizing HS Biologics, Combinations, and Surgery

Knowledge Hub

Toxicity Surveillance for Bispecific Cancer Therapies

Case-Based Learning: Cancer-Associated Thrombosis During Noncytotoxic Therapy

Pharmacokinetic Optimization of Combination Cancer Therapy

Monitoring Delayed Toxicity of Antibody Therapies

Personalized Oncolytic Virus Combinations: Current Evidence and Clinical Implications

Population Surveillance of Environmental Cancer Risk Clusters

Community Strategies for Improving Cancer Prevention Literacy

KOL Videos

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part IV

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Q & A Session

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part III

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II

An In-Depth Look At The Signs And Symptoms Of Lymphoma- Further Discussion

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII

Current Scenario of Cancer- Q&A Session to Close the Gap Part II

Quick Links

Verification

Welcome to Hidoc Dr.

Page Views